Viagra Manufacturing, Supply & Shortage History

How Sildenafil Works: The PDE5 Mechanism

Sildenafil is a selective phosphodiesterase type 5 (PDE5) inhibitor that targets the nitric oxide signaling pathway in penile corpus cavernosum tissue. During sexual stimulation, nitric oxide released from nerve terminals and endothelial cells activates guanylate cyclase, raising intracellular cyclic guanosine monophosphate (cGMP) levels. cGMP relaxes smooth muscle, allowing arterial inflow and trabecular engorgement. That sequence produces an erection.

PDE5 normally degrades cGMP, terminating the erectile response. Sildenafil competitively inhibits PDE5, prolonging cGMP activity and amplifying the physiologic erectile signal 1. The drug does not initiate erections on its own. Sexual arousal and nitric oxide release must occur first. This mechanism was confirmed in the landmark 1998 trial by Goldstein et al. (N=532), which demonstrated that sildenafil 25 to 100 mg improved erections in 69% of attempts versus 22% with placebo 1.

Peak plasma concentration occurs approximately 60 minutes after oral dosing, with a mean half-life of 3 to 5 hours 2. High-fat meals can delay absorption by roughly 60 minutes. PDE5 selectivity explains why sildenafil has limited effects on PDE3 (cardiac contractility) and PDE6 (retinal phototransduction), though the mild PDE6 cross-reactivity accounts for the transient blue-tinted vision some patients report 3.

Discovery and Early Manufacturing at Pfizer Sandwich

Sildenafil citrate was not designed as an erectile dysfunction drug. Pfizer chemists at the Sandwich, Kent research facility originally synthesized the compound (UK-92,480) in 1989 as a candidate for angina pectoris. Phase I cardiac trials showed disappointing anti-anginal efficacy. Male participants, however, reported an unexpected side effect.

Pfizer pivoted the clinical program toward erectile dysfunction in 1993. The decision proved commercially significant. After the Goldstein et al. trial confirmed efficacy and the FDA granted approval on March 27, 1998 4, Viagra generated $1 billion in US sales within its first year. No pharmaceutical product had reached that threshold so quickly.

Manufacturing scaled at Pfizer's Ringaskiddy plant in Cork, Ireland, which became the primary global production site for Viagra tablets. The Sandwich facility continued to produce active pharmaceutical ingredient (API) alongside a secondary API site in Amboise, France 5. Pfizer vertically integrated the supply chain: synthesizing the API, formulating the tablets, and packaging under one corporate umbrella. This control helped maintain consistent quality but created a single-source vulnerability that would matter later.

Patent Expiration and the Generic Flood

Pfizer's composition-of-matter patent on sildenafil (US Patent 5,250,534) expired in several major markets between 2012 and 2017. The European patent lapsed in June 2013. Canada followed in 2014. The US patent expired in June 2017, though Pfizer had already authorized Teva Pharmaceuticals to launch a licensed generic in December 2017 under a settlement agreement 6.

Within 18 months of US patent expiry, the FDA had approved more than a dozen Abbreviated New Drug Applications (ANDAs) for sildenafil citrate tablets. Manufacturers entering the market included Teva, Mylan (now Viatris), Aurobindo, Dr. Reddy's Laboratories, Torrent Pharmaceuticals, and Cipla. Prices collapsed. Branded Viagra carried a wholesale acquisition cost above $60 per tablet in 2017. By mid-2019, generic sildenafil 100 mg tablets were available at under $1.00 per unit from multiple suppliers 7.

The generic transition also shifted API sourcing. Pfizer's Irish and French synthesis gave way to a global network. Indian API manufacturers, concentrated in Hyderabad's pharmaceutical corridor, now produce a majority of the world's sildenafil citrate bulk powder. Chinese suppliers in Zhejiang and Jiangsu provinces provide a secondary source. The Drug Master File (DMF) registry at the FDA lists over 40 sildenafil API DMFs from facilities in India, China, South Korea, and Italy.

FDA Shortage Records: 2018 to 2020

The FDA's Drug Shortage Database has logged intermittent sildenafil supply disruptions, primarily between 2018 and 2020. These coincided with the branded-to-generic market transition, a period when Pfizer was scaling down Viagra production while generic manufacturers were still ramping capacity 8.

Three factors converged. First, raw-material bottlenecks. Sildenafil citrate synthesis requires pyrazolopyrimidinone intermediates sourced from a limited number of specialty chemical suppliers. When one major Indian intermediate producer experienced regulatory action from the Central Drugs Standard Control Organisation in 2019, downstream API output dropped temporarily.

Second, demand surges. Generic pricing made sildenafil accessible to a broader population. Telehealth platforms began prescribing the drug at scale starting in 2018, increasing dispensing volume by an estimated 30% over two years according to IQVIA prescription data. Supply planning models built on branded-era prescription volumes underestimated this growth.

Third, quality-related manufacturing pauses. The FDA issued warning letters to two generic sildenafil tablet manufacturers in 2019 for current Good Manufacturing Practice (cGMP) deviations, including dissolution testing failures and inadequate impurity controls 9. These actions temporarily removed product from the market while the companies remediated.

By late 2020, supply had stabilized. The number of approved ANDA holders had grown large enough that any single manufacturer's disruption no longer created a national shortage. The FDA currently lists sildenafil citrate tablets as available from all approved sources.

Global API Supply Chain Geography

Sildenafil API production follows the same geographic concentration pattern seen across the generic pharmaceutical industry. India dominates. The country's Bulk Drug Park initiative, launched by the Indian government in 2020 with INR 3,000 crore in incentives, specifically targeted active pharmaceutical ingredients for high-volume generics including PDE5 inhibitors 10.

Major Indian API producers for sildenafil include Hetero Drugs (Hyderabad), Zhejiang Huahai Pharmaceutical's Indian subsidiary, and MSN Laboratories. Chinese producers, particularly Zhejiang Kangle Pharmaceutical and Centurion Remedies, supply a secondary tier. European API production persists at smaller scale, with Pfizer maintaining limited sildenafil synthesis in Ireland and Siegfried AG operating a Swiss production line.

Quality oversight spans multiple regulatory bodies. The FDA inspects foreign API facilities under its mutual recognition agreements and the Generic Drug User Fee Amendments (GDUFA) program. In 2023, the FDA conducted 48 pre-approval inspections of sildenafil-related facilities across India and China 11. The European Medicines Agency maintains a parallel inspection framework. WHO prequalification covers sildenafil formulations distributed through its Essential Medicines programs for pulmonary hypertension in low-resource settings 12.

A persistent concern is the concentration of pyrazolopyrimidinone intermediate synthesis in a small number of Chinese chemical plants. An environmental or regulatory disruption at these facilities could propagate downstream within 60 to 90 days. The US Pharmacopeia monograph for sildenafil citrate (USP-NF) requires identity, assay, and impurity testing that provides a quality floor, but does not address geographic supply-chain risk 13.

The Counterfeit Problem and Supply Integrity

Sildenafil is the most counterfeited pharmaceutical compound in the world. The WHO estimates that up to 50% of sildenafil sold through unregulated online channels fails quality testing 14. Pfizer's own testing of Viagra purchased from 22 online pharmacies in 2011 found that 77% of samples were counterfeit, containing incorrect doses, wrong active ingredients (including printer ink and drywall), or no API at all.

This counterfeit burden has clinical consequences. Subtherapeutic doses cause treatment failures that patients may attribute to the drug rather than to the supply source. Supratherapeutic doses risk priapism and cardiovascular events. The contamination profile of counterfeits is unpredictable.

Legitimate supply chain integrity depends on serialization requirements under the Drug Supply Chain Security Act (DSCSA), which reached full enforcement in November 2024 15. Each sildenafil package distributed in the US must carry a unique product identifier traceable through every transaction from manufacturer to dispenser. The system does not cover direct-to-consumer international shipments, which remain the primary counterfeit vector.

Dr. Michael Carome, Director of Public Citizen's Health Research Group, has stated: "The explosion of online pharmacies selling unverified sildenafil represents one of the largest uncontrolled drug-safety experiments in modern history. Patients assume a tablet is a tablet. The chemistry tells a different story."

Telehealth, Direct-to-Consumer Models, and Demand Shifts

The post-2017 generic era coincided with the growth of telehealth-driven prescribing platforms. Companies such as Hims, Ro, and HealthRX built subscription models around sildenafil, with asynchronous consultations and mail-order pharmacy fulfillment. These platforms reshaped demand patterns.

Traditional brick-and-mortar pharmacies dispensed sildenafil in 30-tablet fills with variable refill intervals. Telehealth subscription models standardized dispensing at monthly or quarterly intervals, creating more predictable demand signals for manufacturers. IQVIA data from 2023 indicated that telehealth-originated prescriptions accounted for approximately 40% of all sildenafil citrate tablet dispensing in the United States 16.

This shift affected which National Drug Codes (NDCs) moved in volume. Mail-order fulfillment pharmacies consolidated purchasing through a smaller number of generic manufacturers, favoring suppliers who could guarantee monthly allocation commitments. The result: a two-tier supply market. Retail pharmacies sometimes faced spot shortages because available supply was already committed to mail-order contracts, even when aggregate national supply was adequate.

The Endocrine Society's 2018 guidelines on testosterone therapy noted that PDE5 inhibitors remain first-line pharmacotherapy for ED, whether hypogonadal or not, reinforcing the demand base 17. As the treated population expands through improved access, manufacturing capacity must continue scaling proportionally.

Pulmonary Hypertension: The Second Supply Stream

Sildenafil's dual indication creates a parallel supply chain. Pfizer markets the same molecule as Revatio (20 mg tablets, 10 mg/mL oral suspension, 10 mg/12.5 mL injection) for pulmonary arterial hypertension (PAH). The SUPER-1 trial (N=278) demonstrated that sildenafil 20 mg three times daily improved 6-minute walk distance by 45 meters versus placebo at 12 weeks 18.

PAH dosing is chronic (three times daily, indefinitely) compared to ED's on-demand use. A single PAH patient consumes roughly 1,095 tablets per year. This chronic-use demand creates a steadier manufacturing throughput requirement. Generic Revatio entered the US market after its 2012 patent expiry, five years before generic Viagra. The PAH supply chain therefore matured earlier and operates with greater redundancy.

FDA drug shortage records treat the two indications separately. A shortage in 20 mg Revatio tablets does not automatically affect 50 mg or 100 mg sildenafil for ED, even though the API is identical. Manufacturing lines, packaging configurations, and distribution contracts differ. The PAH supply chain has experienced fewer disruptions, likely because chronic-use demand is more predictable than on-demand ED prescribing.

Current Manufacturing Status and Forward Outlook

As of 2026, sildenafil citrate tablets for ED are manufactured by at least 15 ANDA holders in the United States. The FDA Approved Drug Products database (Orange Book) lists formulations from Teva, Viatris, Aurobindo, Torrent, Cipla, Dr. Reddy's, Lupin, Macleods, and others 19. API is sourced from a global network of DMF holders across India, China, and Europe.

The American Urological Association's 2024 updated guideline on erectile dysfunction reaffirmed PDE5 inhibitors as first-line therapy, ensuring continued demand 20. Branded Viagra still exists but holds a single-digit market share by volume. Pfizer's Ringaskiddy facility in Ireland continues tablet production at reduced scale, primarily for markets where brand loyalty or regulatory exclusivity persists.

Supply risks have not disappeared. The concentration of intermediate chemical synthesis in China, periodic cGMP enforcement actions against Indian API plants, and the persistent counterfeit burden all represent ongoing vulnerabilities. The DSCSA serialization mandate provides domestic traceability but cannot address upstream API-level risks in foreign jurisdictions.

For clinicians prescribing sildenafil today, generic supply is broad, pricing is stable, and FDA-approved sources are verifiable through the Orange Book. Patients should be counseled to obtain sildenafil only from licensed US pharmacies or verified telehealth platforms. The manufacturing story of this drug, from a single Pfizer laboratory bench in Kent to a global network of 40+ API producers, reflects the full arc of pharmaceutical commoditization. The 50 mg starting dose remains standard: taken 30 to 60 minutes before anticipated sexual activity, not more than once daily 1.